Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

: Elevated von Willebrand factor (vWF) levels have been reported in malaria, but their relationship with disease severity remains unclear. This study aimed to compare vWF levels between -infected and uninfected individuals and assess changes in severe infections. : The systematic review was registered in PROSPERO (CRD42024558479). A comprehensive search across six databases identified studies reporting vWF levels in malaria. A meta-analysis was conducted using a random-effects model, with standardized mean difference (SMD) as the effect measure due to varying measurement units. Heterogeneity was assessed using the statistic. : Of 1647 identified records, 26 studies met the inclusion criteria. The meta-analysis showed significantly higher vWF levels in -infected individuals compared to uninfected controls ( < 0.001, SMD: 2.689 [95% CI 1.362; 4.017], : 98.1%, 12 studies, 3109 participants). However, no significant difference was found between severe and less severe cases ( = 0.051, SMD: 3.551 [95% CI -0.007; 7.109], : 99.3%, 8 studies, 1453 participants). : vWF levels are significantly elevated in individuals with infections, indicating a potential role in malaria pathophysiology. Although levels tend to be higher in severe cases, current evidence is insufficient to support vWF as a reliable marker for disease severity. Further prospective and well-controlled studies are needed to validate its diagnostic and prognostic value in malaria management.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12028635PMC
http://dx.doi.org/10.3390/medicina61040767DOI Listing

Publication Analysis

Top Keywords

vwf levels
20
disease severity
12
von willebrand
8
willebrand factor
8
systematic review
8
levels -infected
8
severe cases
8
levels
7
vwf
6
malaria
5

Similar Publications

Levels of placental extracellular vesicles predicts fetal growth restriction and fetal distress in established severe pre-eclampsia.

Int J Gynaecol Obstet

September 2025

Department of Gynecology and Obstetrics, Tianjin Key Laboratory of Female Reproductive Health and Eugenics, Tianjin Medical University General Hospital, Tianjin, China.

Objective: To evaluate whether plasma levels of placental extracellular vesicles (pcEVs), the EV-scavenging factor lactadherin, and prothrombotic markers predict fetal growth restriction (FGR) and/or fetal distress (FD) in established severe pre-eclampsia (sPE).

Methods: We recruited 80 sPE patients, 41 normal pregnancies, and 27 non-pregnant women. SPE patients were further dichotomized into event and non-event groups based on the occurrence of FGR/FD during a follow-up period of 77 days.

View Article and Find Full Text PDF

Introduction  Chronic Obstructive Pulmonary Disease (COPD) is increasingly recognized not only as a pulmonary condition but as a systemic disorder with significant cardiovascular implications. Acute exacerbations of COPD (AECOPD) further elevate this risk, potentially through a heightened prothrombotic state. This study aimed to evaluate and compare the levels of select prothrombotic biomarkers - fibrinogen, C-reactive protein (CRP), D-dimer, von Willebrand Factor (vWF), homocysteine, lactate dehydrogenase (LDH), and platelet-to-lymphocyte ratio (PLR) - in patients with stable COPD and AECOPD, and to assess their diagnostic and prognostic significance.

View Article and Find Full Text PDF

Evaluation of different platelet-dependent von Willebrand factor activity assays to assess the in vivo inhibitory effect of caplacizumab on the von Willebrand factor-platelet interaction.

J Thromb Haemost

September 2025

Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Milan, Italy; Università degli Studi di Milano, Department of Pathophysiology and Transplantation, Milan, Italy. Electronic address:

Background: Caplacizumab, a humanized anti-von Willebrand Factor (VWF) Nanobody®, is employed for immune-mediated Thrombotic Thrombocytopenic Purpura (iTTP) treatment. Its binding to the VWF A1 domain sterically inhibits VWF interaction with platelet glycoprotein Ib (GPIb), counteracting microthrombosis and accelerating the normalization of the platelet count. In caplacizumab-treated iTTP patients with bleeding episodes, measuring platelet-dependent VWF activity (VWF activity) is crucial for monitoring treatment with VWF concentrates.

View Article and Find Full Text PDF

Von Willebrand disease (VWD)-type 1 is a bleeding disorder characterized by a quantitative deficiency of functional von Willebrand factor (VWF). We designed a novel bispecific nanobody, named KB-V13A12, that aims to increase endogenous VWF levels by bridging it to albumin. KB-V13A12 comprises two single-domain antibodies, one targeting VWF and one targeting albumin.

View Article and Find Full Text PDF

Platelet aggregation as a thrombotic marker in cirrhotic patients with portal vein thrombosis.

Clin Exp Hepatol

June 2025

Department of Clinical Pathology, National Liver Institute, Menoufia University, Shebin EL-Kom, Menoufia, Egypt.

Aim Of The Study: Portal vein thrombosis (PVT) is frequently observed in liver cirrhosis patients and correlates with the severity of the underlying liver disease. Thrombocytopenia and thrombocytopathy are signs of liver cirrhosis. A disruption in platelet function may have an impact on the development of thrombosis, considering that platelets are essential in the formation of thrombosis.

View Article and Find Full Text PDF